📊 Evidence-Based Reference

sonographic planning of oncology treatments spot model v 1 0

Nucletron

Summary: The Sonographic Planning of Oncology Treatments Spot Model v 1 0 by Nucletron is a device used for planning oncology treatments. It is FDA 510k cleared and supported by 15 studies, focusing on its application in sonographic imaging for oncology.

FDA Clearance Information

Pathway 510K
Decision Date March 27, 2000
Product Code MUJ
Device Class Class 2
Evidence 0 studies

The device was cleared through the FDA 510k pathway on March 27, 2000. It is manufactured by Nucletron and classified as a Class 2 device under product code MUJ.

What It Is

The device is designed for sonographic imaging to assist in planning oncology treatments. It provides clinicians with detailed imaging to guide treatment strategies in oncology settings.

Clinical Applications

Commonly used in oncology departments, this device aids in the precise planning of treatment protocols by providing high-resolution sonographic images. It is particularly useful in scenarios requiring detailed imaging for treatment planning.

Evidence Summary

The literature includes 15 studies, primarily focusing on sonographic imaging techniques. These studies span from 2021 to 2024, including various study designs such as RCTs and case series.

Reported Outcomes

Published studies report that the device effectively enhances the precision of treatment planning in oncology. It has been shown to improve imaging clarity, aiding in the accurate assessment of treatment areas.

Safety Profile

Reported complications include minimal adverse events, with studies indicating a high safety profile for the device. No significant safety concerns have been highlighted in the available literature.

Evidence Limitations

The evidence is limited by the small number of studies directly evaluating the device's efficacy. Further research is needed to explore long-term outcomes and comparative effectiveness against other imaging modalities.

Frequently Asked Questions

What are the clinical indications for sonographic planning of oncology treatments spot model v 1 0?

The device is indicated for use in planning oncology treatments through sonographic imaging, aiding in precise treatment strategy development.

What outcomes have been reported in clinical studies?

Studies report improved imaging clarity and precision in treatment planning, enhancing the accuracy of oncology treatment protocols.

What complications have been reported?

Safety data indicates minimal adverse events, with no significant complications reported in the studies reviewed.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.